Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, announced an update on the status and outlook of its clinical pipeline programs.

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, announces a business update and outlook for the development of its lead product ...

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and ...

Preparations for pivotal-stage readiness of vididencel in AML on track The hard work of the Mendus team to advance the company's lead product vididencel in acute myeloid leukemia (AML) continued to ...

Mendus and NorthX Biologics will work to develop and commercialize Mendus’ lead asset, vididencel, an allogeneic dendritic cell vaccine. Mendus, a biopharmaceutical company focused on immunotherapies ...

Mendus AB Annual stock financials by MarketWatch. View the latest IMMU financial statements, income statements and financial ratios.

In the third quarter of 2025, Mendus shaped up its clinical development plans for the lead program vididencel in myeloid malignancies. The updated clinical strategy positions vididencel more broadly ...

London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Mendus (OMX: IMMU) Mendus continues to make headway with its lead programme assessing cancer vaccine vididencel ...

ADVANCE II Phase 2 trial data provide basis for late-stage development of lead product vididencel in acute myeloid leukemia Registration trial preparations are ongoing, following positive initial FDA ...